Funding organization: National Institutes of Health (NIH)
Total funding amount: $1,000,000
Duration: Up to 5 years
Primary objective: Support preclinical testing of drug candidates for AD/ADRD
Key stakeholders: Higher education institutions, nonprofits, government entities
Beneficiaries: Researchers and patients affected by AD/ADRD
Eligible organization types include higher education institutions, nonprofits, for-profit organizations, local and state governments, and tribal governments.
Nonprofits must have or not have 501(c)(3) status.
Foreign organizations are eligible to apply.
Eligible applicants can be from the U.S. or foreign organizations.
Non-domestic components of U.S. organizations are allowed.
Projects must focus on preclinical testing of drugs for AD/ADRD.
Applications should propose a streamlined preclinical testing strategy.
Collaboration with industry partners is encouraged.
Application budgets are capped at $1 million in direct costs per year.
No cost-sharing is required.
Application due date: May 7, 2028.
Earliest start date for funded projects: June 9, 2025.
Applicants may submit more than one application, provided each is scientifically distinct.
The NIH will not accept duplicate or overlapping applications.
Applications must follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide.
All required registrations must be completed prior to submission.
Applications will be evaluated based on scientific merit, significance, innovation, rigor, and feasibility.
Applications will undergo peer review by appropriate Scientific Review Groups.
Projects must adhere to open-science principles and maximize data sharing.
Applications proposing only bioinformatics approaches will be considered non-responsive.
Collaboration with experienced researchers in preclinical drug development is crucial.
Avoid submitting overlapping applications.